Age \>= 18 years at time of signing informed consent form (ICF)
Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1
Adequate hematologic and end-organ function
Life expectancy \>= 12 weeks
Patients with histologic documentation of locally advanced, or metastatic solid tumor
\[Dose-escalation Parts and Biopsy Parts\]Refractory or resistant to standard therapies or standard therapies are not available
\[Dose-escalation Parts and Expansion Part\] Patients with confirmed availability of fresh tumor or representative tumor specimens
\[Biopsy Parts\] Patients with accessible lesion(s)
\[Expansion Parts\] Patients with ICI (immune checkpoint inhibitor)-refractory 2L-3L NSCLC (non-small-cell lung cancer) and 3L+ CRC (colorectal cancer)
You may not be if
Clinically significant cardiovascular or liver disease
Treatment with investigational therapy and anti-cancer therapy within 28 days prior to initiation of study drug
Any history of an immune-mediated Grade 4 adverse event attributed to prior cancer immunotherapy (other than asymptomatic elevation of serum amylase or lipase).
All imAEs from prior cancer immunotherapy (other than endocrinopathy managed with replacement therapy, stable vitiligo or stable alopecia) that have not resolved completely to baseline.
Adverse events from prior anti-cancer therapy that have not resolved to Grade ≤ 1 except for alopecia, vitiligo, or endocrinopathy managed with replacement therapy
Primary central nervous system (CNS) malignancy, untreated CNS metastases requiring any anti-tumor treatment, or active CNS metastases
